Lipinski's "Rule of Five" was introduced for predicting oral bioavailability to describe drug-like molecules. For the purpose of this research the rules were used to separate potential inhibitors of HIV-1 integrase (1BIS.pdb) into two groups: drug-like and nondrug-like. If one of Lipinski's "Rule of Five" was not followed the potential inhibitor was classified as nondrug-like. Thirty molecules were identified from the literature, twenty-four drug-like and six nondrug-like, that were docked into the active site of 1BIS.pdb (considered the non-mutated protein) and two mutant models, Y143R and N155H. These are two of the mutations that have led to increased resistance to HIV-1 integrase drugs such as raltegravir and elvitegravir. The computational software, ICMPro (Molsoft L.L.C.), was used to determine the estimated binding energy (EBE) of the drug/protein complex. It was found that the nondrug-like molecules generally had a more negative EBE, that is, tighter binding with 1BIS. pdb, though there were several exceptions in the drug-like group. With the protein mutant model Y143R, the majority of drug-like (58%) and nondruglike molecules (67%) had tighter binding. However, for the mutant model N155H, there was the same percent (46%) of drug-like molecules with tighter binding with the mutant model as with 1BIS.pdb. The drug-like molecules were used when there was a ≥1 kcal/mole difference between 1BIS.pdb and either of the two mutant models to suggest a pharmacophore with structural characteristics for an HIV-1 integrase inhibitor.
Introduction
The Centers for Disease Control and Prevention (CDC) in Healthy People 2020 addressed 10-year national objectives to improve the health of Americans. Of the 600 objectives that cover 42 topic areas, 18 of the objectives focus on HIV and the acquired immunodeficiency syndrome (AIDS). The primary goal of Healthy People 2020 as it relates to HIV/AIDS is to prevent HIV infection and its related illness and death [1] . As of 2015, there are approximately 39,515 new HIV infections each year in the United States [2] . Thus, interventions are needed to prevent transmission to those who are uninfected, and optimized treatment is necessary for those who are already infected. The development of new drugs that can prevent transmission as well as disease progression is of paramount public health importance, and targeting a critical viral enzyme such as HIV-1 integrase is a proven approach to meet this need.
Integrases [3] A simplified model of a drug binding to the active site of a large molecule such as a protein is shown in Figure 1 . When a drug binds to the active site, the estimated binding energy can be computationally calculated from the energy considerations of the different interactions between the drug and the protein. 
HIV-1 Life Cycle
HIV
HIV-1 Integrase Structure and Function
HIV-1 integrase consists of three domains or sections: amino-terminal domain, amino acids 1 -50 (NTD), core catalytic domain, 50 -212 (CCD), and the carboxyl-terminal, 212 -288 (CTD) [8] .
The catalytic core domain of 1BIS.pdb [9] was the focus of the research (Figure 3) . It contains the active site of the protein that is defined by the amino acids: aspartic acid (D) 64, aspartic acid (D) 116, and glutamic acid (E) 152-the DDE triad [10] . Using ICM-Pro [11] , computational software, several pockets were identified but one of the pockets included the active site amino acids, and therefore a binding site for potential drugs. The figure was generated using
HIV-1 integrase catalyzes two biologically relevant nicking reactions ( Figure   4 ): The first reaction (1) (referred to as 3' processing) nicks and trims the 3' end of each strand of unintegrated viral DNA at a specific site. The second reaction (2) (referred to as strand transfer) (ST) inserts the trimmed ends of viral DNA into the two strands of cellular DNA [12] .
Drug-Like and Nondrug-Like Molecules/Inhibitors
Many inhibitors have drug-like properties that follow Lipinski's "Rule of Five" that was introduced for predicting oral bioavailability [13] .
These rules include the following: 1) Molecular mass ≤500 g/mole, 2) Log P (the partition coefficient, defined as the ratio of the concentration of a drug in octanol to its concentration in water) between ±5, 3) Hydrogen bond donors ≤5, and 4) Hydrogen bond acceptors ≤10.
Some integrase inhibitors, however, do not follow these rules. For this research, if an inhibitor failed to follow even one of these rules it was classified as nondrug-like. Using data from ICM-Pro, the inhibitors were divided into two groups-drug-like and nondrug-like. Figure 5 and Figure 6 (generated using ICM-Pro, Molsoft L.L.C.) represent an example of a drug-like [14] and nondrug-like molecule [14] , respectively. The molecules were docked into the active site of 1BIS.pdb [9] and are shown in the potential binding site pocket identified by ICM-Pro. The parameters for Lipinski's Figure 5 . Zhao'14, 5o [14] . Figure 6 . Zhao'14, 5sS [14] . 
Estimated Binding Energy
For the research, the goal was to computationally determine and compare the estimated binding energy (EBE) of a group of drug-like and nondrug-like molecules using 1BIS.pdb and two mutant models of 1BIS.pdb [15] The more negative the ICM-Pro score, the higher the probability the ligand is a binder and could act as a potential drug to block the action of a protein such as HIV-1 integrase. Therefore, the viral DNA could be prevented from integration into the host's DNA. 
The Molecules

Method
Each molecule was docked a minimum of three times within an 8-Å radius of the potential binding site pocket. A 2D ligand interaction of molecule 5sS [14] is displayed in Figure 11 . It represents the interaction of the molecule with the surrounding amino acids of 1BIS.pdb within an 8-Å radius. An average EBE was recorded. However, after docking and before computational determination of the EBE, the best conformer provided by ICM-Pro was chosen based on using crystal structures from the Cambridge Structural Database [19] . The exact molecules were not found in the Cambridge Structural Database, but from communication with a computational chemist at Bristol Myers Squibb [20] , it was suggested that a combination of two to three molecules might be needed to determine the best conformer. For the majority of molecules the first conformer provided by ICM-Pro was the one used to determine the EBE. 
Zhao'14 [14] (Figure 8)
All of the Zhao drug-like molecules have a similar framework of two aromatic fused rings, an amide linker, aromatic ring, and a sidechain off the second ring that is different for each of the molecules. There appears to be stronger binding in 5l, 5n, 5o, and 5p; each of these molecules has a larger sidechain off the second ring. Figure 9 ) Molecules 4, 6, and 7 have a similar framework composed of an aromatic ring, a methyl group linker, aromatic ring, a carbonyl group linker, and two aromatic fused rings. Molecule 7 has a large sidechain off the second ring, that is, a methyl group linked to a sulfonamide group that is part of a ring. This group might contribute to its more negative EBE. Molecule 1 had two aromatic linked rings and a large sidechain off the second ring with three carbonyl groups and an hydroxyl group. Its EBE is similar to molecules 4 and 6.
Zhuang'03 [18] (
Nondrug-Like Molecules
The estimated binding energy of the nondrug-like molecules [14] is shown in Figure 13 . 
Drug-Like Molecules
Approximately 58% of the drug-like molecules had an EBE that was more negative for the mutant model (shown in black) compared to 1BIS.pdb (shown in green) with a ≥1 kcal/mole difference for 33% of the molecules (Figure 17 ).
There were also 33% of the drug-like molecules with 1BIS.pdb in which the EBE was more negative than for the mutant model. Figure 17 . The difference in the EBE between 1BIS.pdb (shown in green) and the mutated protein Y143R (shown in black) with the drug-like molecules. For those where there is a ≥ 1 kcal/mole difference they are marked with .
Nondrug-Like Molecules
For the nondrug-like molecules, there were four molecules with tighter binding with the mutant model-the 5r and 5t molecules-R and S configuration ( Figure 18 ). However, for 5sR and 5sS there was tighter binding wth 1BIS.pdb. 
Results of the Estimated Binding Energies with 1BIS.pdb, Mutation N155H
This mutation is also referenced in the HIV Drug Resistance Database [15] and has led to increased resistance of the HIV-1 integrase drugs raltegravir and elvi- 
Drug-Like Molecules
Approximately 46% of the drug-like molecules had an EBE that was more negative with the mutant model than with 1BIS.pdb ( Figure 22 ). There was a ≥1 Figure 19 . Asparagine and histidine. 
Nondrug-Like Molecules
In four of the six molecules 1BIS.pdb had a more negative EBE: 5rS, 5sR, 5sS, and 5tR. Two molecules had a more negative EBE with the mutant model: 5rR and 5tS (very slight). There appears to be no structural pattern to tighter binding in the nondrug-like group. In one molecule, 5sR, there was a ≥1 kcal/mole difference with 1BIS.pdb ( Figure 23 ). Figure 23 . The difference in the EBE using 1BIS.pdb (shown in red) and the mutant model N155H (shown in black) for the nondrug-like molecules.
Discussion
1BIS.pdb
Though drug-like characteristics as defined by Lipinski's "Rule of Five" were introduced for predicting oral bioavailability, the rules were used to classify 30 potential inhibitors of 1BIS.pdb into two groups. The goal was to examine the es- There were seven drug-like molecules with EBE ≥−10 kcal/mole: Barreca 36
and 37, Zhao 5l, 5n, 5o, and 5p, and Zhuang 7. Barreca 36 and 37 were similar in structure except Barreca 37 had a fluorine on the first ring, and a more negative EBE than Barreca 36. Both of these had a sidechain off the indole group with two carbonyl groups and an ethoxide group to contribute to additional interactions.
All of the Zhao molecules had the same basic structure except for a sidechain off the second ring. The sidechain of the four Zhao molecules (5l, 5n, 5o, and 5p)
was large compared to the other Zhao molecules and could contribute to hydrophobic (5-carbon extension) or hydrogen bond (−NH 2 group, 2-carbon sidechain plus an hydroxyl group, 2-carbon extension plus an ester) interactions with the protein and therefore tighter binding. The structure of Zhuang 7 was similar to the other Zhuang molecules except there was a sidechain with a cyclic sulfonamide group. The number of HBA for the Zhuang 7 molecule was 10 and HBD, one, so there were more increased possibilities for hydrogen bond interactions.
Mutant Model, Y143R
There were structural considerations for mutation of tyrosine ( 
Mutant Model, N155H
Asparagine ( Barreca 37 also had a chlorine off the fused ring. They differed somewhat in their sidechains but their EBE was similar.
With two exceptions, 5rR and 5tS, the nondrug-like molecules had tighter binding with 1BIS.pdb. Structurally one was an R configuration and the other S and there was only one more HB interaction for 5tS. These differences had a minor impact on the EBE of the drug with the mutant model. There was one molecule, 5sR, with a ≥1 kcal/mole difference between 1BIS.pdb and the mutant model with tighter binding with 1BIS.pdb. The EBE with 1BIS.pdb was −12.9 kcal/mole and −9.8 kcal/mole with the mutant model.
Conclusions
Do the molecules with tighter binding, with either of the two mutant models, share structural characteristics that might be important when designing drugs for HIV-1 integrase? To answer the question, the structure of the drug-like molecules was considered when there was a ≥1 kcal/mole difference between 1BIS.
pdb and either of the two mutant models. The two mutations, however, are only two of a number of HIV-1 integrase mutations that have led to increased resistance of HIV-1 integrase drugs such as raltegravir and elvitegravir [15] .
The drug-like molecules were the following: Barreca 19, 21, 40 , 41, and 43;
Zhao 5e, 5l, and 5v; and Zhuang 1 and 7. To address the structural characteristics that the 10 molecules share in common, a pharmacophore ( Figure 24 ) was developed using a 3D pharmacophoric potential implemented on a grid [22] .
The IUPAC defines a pharmacophore as "an ensemble of steric and electronic Figure 24 . Pharmacophore developed using atomic property fields. The figure was computationally generated by Andy Orry, Molsoft, L.L.C.
features that is necessary to ensure the optimal supramolecular interactions with a specific biological target and to trigger (or block) its biological response" [23] .
Using the Atomic Property Fields (APF) developed by Molsoft, L.L.C. [22] seven properties are assigned from empiric physico-chemical components [22] : hydrogen bond donors and acceptors, sp 2 hybridization, lipophilicity, size, electropositive/negative, and charge. The structural properties of the pharmacophore that contribute to interactions between a drug and active site amino acids are displayed in Figure 24 .
The most obvious feature of the pharmacophore is the aromaticity of the rings (shown in white). All of the molecules had some combination of single aromatic rings and/or two fused rings-a common feature in HIV-1 integrase drugs [24] .
The aromaticity allows for π − π stacking with amino acids in the active site.
There were a greater number of hydrogen bond acceptors (shown in red), than 
